Pfizer Shakes Up C-Suite, Elevating Cancer Chief Boshoff to CSO
Chris Boshoff will take over as Pfizer’s next chief scientific officer as of January 1, replacing Mikael Dolsten who led the pharma through the COVID-19 pandemic. The move comes weeks after Pfizer faced pressure from activist investor Starboard Value.
BridgeBio Pharma Inc. gained US approval for a drug to treat a progressive and deadly form of heart disease, paving the way ...
The pharma leader is betting that streamlined services may be a shot in the arm for Americans seeking care with its ...
Pfizer shares are trading lower by 10% in November. President-elect Donald Trump last week announced his intention to nominate Robert F. Kennedy Jr. to lead the HHS.
Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own ...
A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange ...
The Motley Fool on MSN3d
Is It Time to Sell Eli Lilly and Pfizer Stocks?Lilly and Pfizer stocks have sold off sharply in recent weeks. Both drugmakers have had some bad news that caused their ...
Pfizer has found a successor for retiring Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the ...
For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the ...
Zai Lab and Pfizer Inc. are teaming up in China to fight the deadly carbapenem-resistant Acinetobacter baumannii (CRAB) infection with novel antibacterial drug Xacduro (sulbactam-durlobactam).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback